Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease | Zendy

John L. Lyles | Zendy; Aditi Mulgund | Zendy; Laura Bauman | Zendy; Weizhe Su | Zendy; Lin Fei | Zendy; Deepika L. Chona | Zendy; Puneet Sharma | Zendy; Renee K. Etter | Zendy; Jennifer Hellmann | Zendy; Lee A. Denson | Zendy; Phillip Minar | Zendy; Dana M. H. Dykes | Zendy; Michael J. Rosen | Zendy

Open Access

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

Author(s) -

John L. Lyles,

Aditi Mulgund,

Laura Bauman,

Weizhe Su,

Lin Fei,

Deepika L. Chona,

Puneet Sharma,

Renee K. Etter,

Jennifer Hellmann,

Lee A. Denson,

Phillip Minar,

Dana M. H. Dykes,

Michael J. Rosen

Publication year - 2020

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izaa102

Subject(s) - inflammatory bowel disease , medicine , therapeutic drug monitoring , drug , intensive care medicine , disease , tumor necrosis factor alpha , inflammatory bowel diseases , pharmacology

Reports on the feasibility and effectiveness of translating proactive, antitumor necrosis factor (TNF) therapeutic drug monitoring (TDM) for inflammatory bowel disease into practice-wide quality improvement (QI) are lacking. We aimed to determine whether a TDM QI program improved outcomes at a large academic pediatric gastroenterology practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research